The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain types of bacterial ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

Because the effectiveness of the current oral options ... review discusses various topical antibiotic treatment options for uncomplicated skin infections, including over-the-counter and prescribed ...

Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...

The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

Both mupirocin and retapamulin demonstrated high clinical success rate in SIDs, but did not show significant superiority to oral antimicrobials ... treatment failure or re-infection, especially ...

It could be a way to combat antibiotic resistance, but it’s also the treatment you want tell your friends about.

The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades--Company ...

oral antibiotic for adult and adolescent females with uncomplicated urinary tract infections (uUTIs). The FDA has granted Priority Review for this application and assigned a Prescription Drug User ...

The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...